TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06925542: A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease

Sponsor: CRISPR Therapeutics · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$3,941,280

Rescue Site Savings

+$2,604,060

Unlock Full NCT06925542 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06925542 Rescue Dossier →